
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Cardio Diagnostics Holdings Inc (CDIOW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CDIOW (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.75% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.06 | 52 Weeks Range 0.01 - 0.18 | Updated Date 05/17/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -173463.83% |
Management Effectiveness
Return on Assets (TTM) -43.94% | Return on Equity (TTM) -81.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1605873 |
Shares Outstanding - | Shares Floating 1605873 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cardio Diagnostics Holdings Inc
Company Overview
History and Background
Cardio Diagnostics Holdings Inc. is a cardiovascular precision medicine company that aims to improve prevention, detection, and management of cardiovascular disease through integrated genomics and artificial intelligence. Founded relatively recently, it has focused on developing diagnostic tests and tools leveraging AI.
Core Business Areas
- Precision Cardiovascular Diagnostics: Focuses on developing and commercializing integrated genetic-clinical risk assessment tools to predict cardiovascular events.
- AI-Driven Analysis: Applies artificial intelligence and machine learning to patient data for enhanced cardiac risk assessment.
Leadership and Structure
Information regarding its leadership team and detailed organizational structure can be found on their investor relations page. This section would include names and titles such as CEO, CFO and board members along with the departments and number of staff in each one.
Top Products and Market Share
Key Offerings
- Epi+Gen CHD: A blood-based test utilizing epigenetics and genetics to assess a patient's risk of coronary heart disease (CHD). Market share data is currently limited due to the competitive landscape with companies like Myriad Genetics and Exact Sciences. Revenue data can be sourced on their investor relations page.
- Epi+Gen CVD: Broader cardiovascular disease risk assessment test. Market share data is currently limited due to the competitive landscape with companies like Myriad Genetics and Exact Sciences. Revenue data can be sourced on their investor relations page.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is growing due to aging populations, increasing prevalence of heart disease, and advancements in diagnostic technologies. Personalized medicine and AI are driving innovation.
Positioning
Cardio Diagnostics is positioned as an innovative player leveraging AI and genomics in cardiovascular risk assessment. They aim to differentiate through precision and personalized insights.
Total Addressable Market (TAM)
The global cardiovascular diagnostics market is expected to reach billions of dollars. Cardio Diagnostics aims to capture a portion of this TAM through its novel diagnostic solutions.
Upturn SWOT Analysis
Strengths
- Proprietary AI-driven platform
- Focus on personalized cardiovascular medicine
- Novel epigenetic approach
- Potential for improved diagnostic accuracy
Weaknesses
- Limited market penetration
- Reliance on funding
- Relatively small company size
- Limited revenue
Opportunities
- Expanding market for precision medicine
- Partnerships with healthcare providers
- Increased adoption of AI in diagnostics
- Development of new diagnostic tests
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- MYGN
- EXAS
- MDT
Competitive Landscape
Cardio Diagnostics competes with larger, more established diagnostic companies. Its advantage lies in its AI-driven approach and focus on precision cardiovascular medicine. Its disadvantage is its smaller size and limited market penetration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can be derived from the financial reports on their investor relations website.
Future Projections: Analyst estimates for future growth can be sourced from financial news outlets. Investors.com, and Yahoo Finance.
Recent Initiatives: Recent initiatives are located in press releases from the company on their investor relations page. These include partnerships and product development milestones.
Summary
Cardio Diagnostics is a relatively new company in the cardiovascular diagnostics space leveraging AI and genomics. While its AI-driven approach is promising, the company faces challenges from established competitors and needs to demonstrate sustainable growth. Its success depends on securing partnerships, expanding market reach, and achieving favorable reimbursement for its tests. The company's limited revenue and reliance on funding present significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website (Investor Relations)
- SEC Filings
- Financial News Outlets (e.g., Yahoo Finance, Investors.com)
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data may be estimated. Financial data is based on publicly available information and may not be exhaustive. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardio Diagnostics Holdings Inc
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-01-14 | Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://cdio.ai |
Full time employees 13 | Website https://cdio.ai |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.